Tuttle R L, Knick V C, Stopford C R, Wolberg G
Cancer Res. 1983 Jun;43(6):2600-5.
Growth of a primary tumor is often accompanied by the development of resistance to subsequent challenge implants of the same tumor, i.e., concomitant immunity. Using the P815 mastocytoma tumor, the kinetics of concomitant immunity was found to be governed by duration of exposure to the tumor and tumor mass. By implanting small "challenges" prior to the immunizing tumor, resistance to the growth of existing tumor foci was demonstrated. Winn-type assays revealed that antitumor activity was present in cell populations from the peritoneal exudate and lymph node draining the tumor. Peritoneal exudate cells, when infused systemically, were also able to confer protection against P815 mastocytoma challenge, suggesting their role as mediators of concomitant immunity. The 51Cr release technique indicated that cytolytic activity in lymph node cells, peritoneal exudate cells, and the spleen was present over a time course parallel to the kinetics of in vivo challenge. The peritoneal resident cell population was only slightly active; thus, effectors accumulated in the inflammatory exudate. Removal of specific subsets of cells from effector populations with antibody to surface markers and complement produced similar effects on both Winn and cytolytic assays. Anti-Thy 1.2 ablated measurable activity. It was substantially but not completely reduced by anti-Lyt 1.1 and only to a small degree by anti-Lyt 2.1.
原发性肿瘤的生长通常伴随着对同一肿瘤后续攻击植入物产生抗性，即伴随免疫的发展。利用P815肥大细胞瘤，发现伴随免疫的动力学受肿瘤暴露持续时间和肿瘤大小的支配。通过在免疫肿瘤之前植入小的“攻击物”，证明了对现有肿瘤病灶生长的抗性。Winn型试验表明，肿瘤引流部位的腹膜渗出液和淋巴结中的细胞群体具有抗肿瘤活性。当全身注入腹膜渗出液细胞时，它们也能够提供针对P815肥大细胞瘤攻击的保护作用，表明它们作为伴随免疫介质的作用。51Cr释放技术表明，淋巴结细胞、腹膜渗出液细胞和脾脏中的细胞溶解活性在与体内攻击动力学平行的时间进程中存在。腹膜常驻细胞群体活性较低；因此，效应细胞在炎性渗出液中积累。用针对表面标志物的抗体和补体从效应细胞群体中去除特定细胞亚群，对Winn试验和细胞溶解试验产生类似影响。抗Thy 1.2消除了可测量的活性。抗Lyt 1.1使其显著但未完全降低，抗Lyt 2.1仅使其稍有降低。
